

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-26. (Cancelled)

27. (Currently Amended) A method for the treatment of a patient suffering from symptoms associated with a condition selected from the group consisting of negative symptoms of schizophrenia, cognitive dysfunction in schizophrenia, refractory schizophrenia, suicidality and mild cognitive impairment with a pharmaceutically effective amount of a compound having a relative 5-HT_{2C} affinity of ≥ 1.80 , wherein the relative 5HT_{2C} affinity is determined according to Formula I:

$$\text{Formula I: } \frac{X}{A} + \frac{X}{B} = Y$$

wherein X is the average affinity of a compound for interaction at the 5HT_{2C} receptor and A and B are the average affinity values of a compound for interaction at two major sites other than the 5HT_{2C} receptor, with the proviso that:

(a) when the condition is selected from the group consisting of negative symptoms of schizophrenia, cognitive dysfunction in schizophrenia and refractory schizophrenia, the compound is other than ritanserin, clozapine, fluperlapine, loxapine, ORG-5222, pipamperone, sertindole, olanzapine, zotepine or ziprasidone;

(b) when the condition is selected from the group consisting of cognitive dysfunction in schizophrenia and mild cognitive impairment, the compound is other than (1R,2S,4R)-(-)-2-phenyl-2-(dimethylaminoethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane,

(1R,2S,4R-(-)-2-phenyl-2-(methylaminoethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane
and pharmaceutically acceptable acid addition salts thereof; and

_____ (c) _____ when the condition is schizophrenic suicidality, the compound is
other than clozapine

~~A method for the treatment of a patient suffering from symptoms associated with
a condition selected from the group consisting of negative symptoms of schizophrenia,
cognitive dysfunction in schizophrenia, refractory schizophrenia, suicidality and mild
cognitive impairment with a pharmaceutically effective amount of a compound having a
relative 5-HT_{2C} affinity of ≥ 1.80 , wherein the relative 5-HT_{2C} affinity is determined
according to the method of claim 20 with the proviso that:~~

~~(a) _____ when the condition is selected from the group consisting of negative
symptoms of schizophrenia, cognitive dysfunction in schizophrenia and refractory
schizophrenia, the compound is other than ritanserin, clozapine, fluperlapine, loxapine,
ORG-5222, pipamperone, sertindole, olanzapine, zotepine or ziprasidone;~~

~~(b) _____ when the condition is selected from the group consisting of cognitive
dysfunction in schizophrenia and mild cognitive impairment, the 5-HT_{2C} receptor
antagonist is other than (1R,2S,4R)-(-)-2-phenyl-2-(dimethylaminoethoxy)-1,7,7-
trimethyl-bicyclo[2.2.1]heptane, (1R,2S,4R)-(-)-2-phenyl-2-(methylaminoethoxy)-1,7,7-
trimethyl-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts
thereof; and~~

~~(c) — when the condition is schizophrenic suicidality, the compound is other than clozapine.~~

28. (Previously Presented) A method according to claim 27 wherein the condition is refractory schizophrenia, with the proviso that the compound is other than ritanserin, clozapine, fluperlapine, loxapine, ORG-5222, pipamperone, sertindole, olanzapine, zotepine or ziprasidone.

29. (Previously Presented) A method according to claim 27 wherein the condition is suicidality, with the proviso that, when the suicidality is in a schizophrenic patient, the compound is other than clozapine.

30. (Previously Presented) A method according to claim 29, wherein the suicidality is in a schizophrenic patient.

31. (Previously Presented) A method according to claim 27 wherein the condition is mild cognitive impairment with the proviso that the compound is other than deramciclane or N-desmethylderamciclane.

32. (Previously Presented) A method according to claim 27 wherein the compound is as described in a publication selected from the group consisting of WO 97/16429, WO 97/44334, US 05010078, EP 161,218, EP 401,707, EP 526,434, DE 02834114, EP 210,893, US 03580916, US 05043341, EP 620,222, EP 208,235, EP 437,790, DE 02614406, US 04338317, EP 271,013, EP 110,435, EP 398,326, WO 92/05170, WO 95/01976, WO 96/23783, WO 98/04289, WO 97/48700, WO 00/48602, WO 00/26186, WO 99/58490, WO 99/52517, WO 99/51237, WO 99/46245, WO

99/43319, WO 99/33841, WO 99/33840, WO 99/25356, WO 99/09017, WO 99/03833,
WO 99/00119, WO 98/56367, WO 98/52943, WO 98/50358, WO 98/50346, WO
98/50343, WO 98/41527, WO 98/38165, WO 98/30561, WO 98/30546, WO 98/24785,
WO 98/21958, WO 98/04261, WO 97/48699, WO 97/41858, WO 97/39001, WO
97/37989, WO 97/20845, WO 97/12880, WO 97/08167, WO 97/06155, WO 97/00872,
WO 96/39382, WO 96/30366, WO 96/24351, WO 96/23769, WO 96/18629, WO
96/14320, WO 96/11930, WO 96/11929, WO 96/02537, WO 95/29177, WO 95/25731,
WO 95/24194, WO 95/21844, WO 95/18117, WO 95/12591, WO 94/22871, WO
94/18958, WO 94/18182, WO 94/18170, WO 94/14801, WO 94/04533, WO 94/02462,
WO 93/18028, WO 93/18026, WO 93/16081, WO 93/16051, WO 93/14758, WO
93/12790, WO 92/15302, WO 92/10192, WO 91/18602, WO 01/68585, WO 01/68067,
WO 01/52855, WO 01/38329, WO 01/26621, WO 01/25229, WO 01/19371, WO
00/76984, WO 00/68181, WO 00/63185, WO 00/62782, WO 00/61129, WO 00/61128,
WO 00/37068, WO 00/06165, US 06143325, US 05854248, US 05739336, US
05693645, US 05674875, US 05498618, US 05371093, US 05266571, US 05116852,
US 05106855, US 05030656, US 05013735, US 04985352, US 04914107, US
04914100, US 04906639, US 04902691, US 04891376, US 04847261, JP 13220375,
JP 12204040, JP 11171865, JP 11080155, JP 10316634, JP 10077271, JP 09040646,
JP 08053416, JP 08040999, JP 07228573, JP 07179337, JP 00158067, GB 02303303,
GB 02301774, EP 01118610, EP 1070716, EP 01052245, EP 01000944, EP 00905136,
EP 00797995, EP 00797994, EP 00769297, EP 00749971, EP 00749967, EP
00718299, EP 00700905, EP 00686393, EP 00682015, EP 0661266, EP 00657426, EP
006554440, EP 00613898, EP 00596449, EP 00559569, EP 00545120, EP 00522226,

EP 00511074, EP 00511073, EP 00493687, EP 00484988, EP 00465398, EP 00452074, EP 00389352, EP 00388081, EP 00384228, EP 00379308, EP 00378468, EP 00375297, EP 00374042, EP 00373998, EP 00363963, EP 00354030, EP 00337136, EP 00332528, EP 00320983, EP 00218433 and EP 00145494.

33. (Previously Presented) A method according to claim 27 in which the compound is selected from the group consisting of AHR-16303B (AH Robins Co. Inc), AP-792 and AT-1015 (Ajinomoto Co. Inc.), BMS-181102 (Bristol Myers Squibb), CV-5197 (Takeda Chemical Industries Ltd), dotarizine (Ferrer Internacional SA), E-2101 (Eisai Co Ltd), eltoprazine (Solvay SA), emopamil (Knoll AG), HT-90B (Chugai Pharmaceutical Co Ltd), ICI-169369 and ICI-170809 (Zeneca Group plc), LU-26042 and LU-29066 (H Lundbeck A/S), NPC-18166 (Scios Inc), Org-38457 (NV Organon), pelanserin (Cinvestav), perbufylline (Siegfried Group), SB-206553 and SB-242084 (SmithKline Beecham), SR-46615A (Sanofi Recherche SA), SUN-9221 (Suntory Ltd) tropoxin (Russian Academy Medical Science) and YM-992 (Yamanouchi Pharmaceutical Co Ltd).

34. (Previously Presented) A method according to claim 27 in which the compound is selected from the group consisting of Ro-60-0759, RS-102221, SDZ-SER-082, ICI-169369, deramciclane, N-desmethyl-deramciclane, amesergide, sergolexole, CGS-18102A and LU-26042.

35. (Previously Presented) A method according to claim 34 in which the compound is selected from the group consisting of deramciclane, N-desmethyl-deramciclane, amesergide, sergolexole, CGS-18102A and LU-26042.

36. (Previously Presented) A method according to claim 27 wherein the condition is suicidality or mild cognitive impairment and wherein the compound is selected from the group consisting of ritanserin, clozapine, fluperlapine, loxapine, ORG-5222, pipamperone, sertindole, olanzapine, zotepine and ziprasidone, with the proviso that when the suicidality is in a schizophrenic patient, the compound is other than clozapine.

37. (Previously Presented) A method for the treatment of a patient suffering from symptoms associated with a condition selected from the group consisting of refractory schizophrenia, suicidality and mild cognitive impairment with a pharmaceutically effective amount of a 5-HT_{2C} receptor antagonist with the proviso that:

(a) when the condition is refractory schizophrenia, the 5-HT_{2C} receptor antagonist is other than ritanserin, clozapine, fluperlapine, loxapine, ORG-5222, pipamperone, sertindole, olanzapine, zotepine or ziprasidone;

(b) when the condition is mild cognitive impairment, the 5-HT_{2C} receptor antagonist is other than (1R,2S,4R)-(-)-2-phenyl-2-(dimethylaminoethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane, (1R,2S,4R)-(-)-2-phenyl-2-(methylaminoethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof; and

(c) when the condition is schizophrenic suicidality, the 5-HT_{2C} receptor antagonist is other than clozapine.

38. (Previously Presented) A method according to claim 37 wherein the condition is refractory schizophrenia, with the proviso that the antagonist is other than ritanserin, clozapine, fluperlapine, loxapine, ORG-5222, pipamperone, sertindole, olanzapine, zotepine or ziprasidone.

39. (Previously Presented) A method according to claim 37 wherein the condition is suicidality, with the proviso that, when the suicidality is in a schizophrenic patient, the 5-HT_{2C} receptor antagonist is other than clozapine.

40. (Previously Presented) A method according to claim 39, wherein the suicidality is in a schizophrenic patient.

41. (Previously Presented) A method according to claim 37 wherein the condition is mild cognitive impairment with the proviso that the antagonist is other than deramciclane or N-desmethylderamciclane.

42. (Previously Presented) A method according to claim 37 wherein the 5-HT_{2C} receptor antagonist is as described in a publication selected from the group consisting of WO 97/16429, WO 97/44334, US 05010078, EP 161,218, EP 401,707, EP 526,434, DE 02834114, EP 210,893, US 03580916, US 05043341, EP 620,222, EP 208,235, EP 437,790, DE 02614406, US 04338317, EP 271,013, EP 110,435, EP 398,326, WO 92/05170, WO 95/01976, WO 96/23783, WO 98/04289, WO 97/48700, WO 00/48602, WO 00/26186, WO 99/58490, WO 99/52517, WO 99/51237, WO 99/46245, WO 99/43319, WO 99/33841, WO 99/33840, WO 99/25356, WO 99/09017, WO 99/03833,

WO 99/00119, WO 98/56367, WO 98/52943, WO 98/50358, WO 98/50346, WO
98/50343, WO 98/41527, WO 98/38165, WO 98/30561, WO 98/30546, WO 98/24785,
WO 98/21958, WO 98/04261, WO 97/48699, WO 97/41858, WO 97/39001, WO
97/37989, WO 97/20845, WO 97/12880, WO 97/08167, WO 97/06155, WO 97/00872,
WO 96/39382, WO 96/30366, WO 96/24351, WO 96/23769, WO 96/18629, WO
96/14320, WO 96/11930, WO 96/11929, WO 96/02537, WO 95/29177, WO 95/25731,
WO 95/24194, WO 95/21844, WO 95/18117, WO 95/12591, WO 94/22871, WO
94/18958, WO 94/18182, WO 94/18170, WO 94/14801, WO 94/04533, WO 94/02462,
WO 93/18028, WO 93/18026, WO 93/16081, WO 93/16051, WO 93/14758, WO
93/12790, WO 92/15302, WO 92/10192, WO 91/18602, WO 01/68585, WO 01/68067,
WO 01/52855, WO 01/38329, WO 01/26621, WO 01/25229, WO 01/19371, WO
00/76984, WO 00/68181, WO 00/63185, WO 00/62782, WO 00/61129, WO 00/61128,
WO 00/37068, WO 00/06165, US 06143325, US 05854248, US 05739336, US
05693645, US 05674875, US 05498618, US 05371093, US 05266571, US 05116852,
US 05106855, US 05030656, US 05013735, US 04985352, US 04914107, US
04914100, US 04906639, US 04902691, US 04891376, US 04847261, JP 13220375,
JP 12204040, JP 11171865, JP 11080155, JP 10316634, JP 10077271, JP 09040646,
JP 08053416, JP 08040999, JP 07228573, JP 07179337, JP 00158067, GB 02303303,
GB 02301774, EP 01118610, EP 1070716, EP 01052245, EP 01000944, EP 00905136,
EP 00797995, EP 00797994, EP 00769297, EP 00749971, EP 00749967, EP
00718299, EP 00700905, EP 00686393, EP 00682015, EP 0661266, EP 00657426, EP
006554440, EP 00613898, EP 00596449, EP 00559569, EP 00545120, EP 00522226,
EP 00511074, EP 00511073, EP 00493687, EP 00484988, EP 00465398, EP

00452074, EP 00389352, EP 00388081, EP 00384228, EP 00379308, EP 00378468, EP 00375297, EP 00374042, EP 00373998, EP 00363963, EP 00354030, EP 00337136, EP 00332528, EP 00320983, EP 00218433 and EP 00145494.

43. (Previously Presented) A method according to claim 37 in which the 5-HT_{2C} receptor antagonist is selected from the group consisting of AHR-16303B (AH Robins Co. Inc), AP-792 and AT-1015 (Ajinomoto Co. Inc.), BMS-181102 (Bristol Myers Squibb), CV-5197 (Takeda Chemical Industries Ltd), dotarizine (Ferrer Internacional SA), E-2101 (Eisai Co Ltd), eltoprazine (Solvay SA), emopamil (Knoll AG), HT-90B (Chugai Pharmaceutical Co Ltd), ICI-169369 and ICI-170809 (Zeneca Group plc), LU-26042 and LU-29066 (H Lundbeck A/S), NPC-18166 (Scios Inc), Org-38457 (NV Organon), pelanserin (Cinvestav), perbufylline (Siegfried Group), SB-206553 and SB-242084 (SmithKline Beecham), SR-46615A (Sanofi Recherche SA), SUN-9221 (Suntory Ltd) tropoxin (Russian Academy Medical Science) and YM-992 (Yamanouchi Pharmaceutical Co Ltd).

44. (Previously Presented) A method according to claim 37 in which the 5-HT_{2C} receptor antagonist is selected from the group consisting of Ro-60-0759, RS-102221, SDZ-SER-082, ICI-169369, deramciclone, N-desmethyl-deramciclone, amesergide, sergolexole, CGS-18102A and LU-26042.

45. (Previously Presented) A method according to claim 44 in which the 5-HT_{2C} receptor antagonist is selected from the group consisting of deramciclone, N-desmethyl-deramciclone, amesergide, sergolexole, CGS-18102A and LU-26042.

46. (Previously Presented) A method according to claim 37 wherein the condition is suicidality or mild cognitive impairment and wherein the 5-HT_{2C} receptor antagonist is selected from the group consisting of ritanserin, clozapine, fluperlapine, loxapine, ORG-5222, pipamperone, sertindole, olanzapine, zotepine and ziprasidone, with the proviso that when the suicidality is in a schizophrenic patient, the 5-HT_{2C} receptor antagonist is other than clozapine.

Claims 47-51. (Canceled)

52. (New) A method according to claim 27 wherein the compound is selected from the group consisting of deramciclane and N-desmethyl-deramciclane.